With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Patients presenting with STEMI represent a high-risk population. Thrombotic and bleeding complications contribute to mortality in these patients. Join Drs. Steg, Hamm, Hill, and Mehran as they discuss best practices for the treatment of STEMI patients with a focus on preventing bleeding complications.
Studies suggest that major bleeding is associated with a 5-fold increase in the risk for death among ACS patients. Join our expert panel: Profs. Hamm, Kristensen, and Spaulding as they discuss treatment options and strategies to reduce bleeding in STEMI patients.
iQandA, The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine.
New data surrounding the treatment of patients with ACS has led to confusion as to what is the best therapeutic option for a given patient. Join Drs. Sameer Mehta, Michel Le May, Tim Henry, and Michael Mooney as they discuss these data and their applicability to clinical practice.
Join Drs Harrington and Anderson as they discuss the difficult issues surrounding the choice of antithrombotic choices and the medical and interventional management of patients with UA/STEMI.
National Infarct Angioplasty Project (NIAP) recommends infarct angioplasty as the primary treatment for STEMI. Please join Drs Hill, Kapur, Banning, Van de Werf, and Gray as they discuss the importance and primary findings of the NIAP report.
Aggressive implementation of antiplatelet therapy has significantly decreased adverse cardiovascular events, such as death, myocardial infarction, and stroke in STEMI patients. Join Duke Clinical Research Institute's Drs Harrington and Alexander as they review the data and guidelines for the medical management of STEMI patients.
In May 2008, the HORIZONS-AMI study showed that anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events in patients with ST-segment elevation myocardial infarction who are undergoing primary PCI. Join Dr Mehran for an update on this study and a discussion of its applications to clinical practice.